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ipercalcemia  y  nefrocalcinosis  com
e  los  fármacos  para  mejorar  el  ren
ear Editor,
hronic hypercalcemia can be an important complica-
on of anabolic steroid and vitamin supplement abuse.
e report the case of a 30-year-old bodybuilder that for
ore  than 4 years used injectable anabolic-androgenic
eroids (AAS) and one veterinary polyvitamin formulation
ith vitamin A (2,100,000 IU), D (ergocalciferol: 60,000 IU),
d E (55 IU) on a monthly basis. He also reported self-
jecting mineral oil intramuscularly for esthetic purposes
r more  than 2 years. He presented to the emergency
om with an acute, severe epigastric pain, associated
ith nausea and vomiting. Laboratory evaluation (Table 1)
emonstrated an elevated amylase 2500 IU/L (50–160 IU/L);
pase of 612 IU/L (0–75 IU/L); a corrected serum calcium of
.5 mg/dL (8.5–10.5 mg/dL); PTH of 73.2 pg/mL (15–68.3 pg/mL)
d 25(OH)D of 65.1 ng/mL (30–100 ng/mL). Serum creatinine
as 1.2 mg/dL (0.6–1.2 mg/dL). Abdominal ultrasound showed
diffusely edematous pancreas, bilateral ureterolithiasis and
ephrocalcinosis. A high-resolution CT of the chest and
domen was performed and revealed absence of granulomas
d lymphadenopathies. He had a tormented clinical course,
ith acute kidney injury (attributed to volume depletion
d renal vasoconstriction in the setting of hypercalcemia)
ithout the need of hemodialysis; protracted vomiting that
ad to a laparoscopic duodenum–jejunum anastomosis with
provement of complains and multiple infectious compli-
tions. Serum calcium and PTH returned to normal levels
 mg/dL and 35 pg/mL, respectively) after vitamin D discon-
nuation, vigorous venous hydration with 0.9% saline infusion
d therapy with furosemide and corticosteroids. After more
an 60 days of hospitalization he was discharged home hav-
g made a full recovery.
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With the desire to improve performance, some athletes or
ateurs use performance-enhancing drugs. The widespread
se of these substances without medical prescription or clini-
l follow-up can lead to serious health problems as described
n several reports.1–3 We believe that the main clinical fea-
res seen in this patient are due to chronic hypercalcemia due
 multiple substance abuse and parafﬁnomas. The associa-
on between focal segmental glomerulosclerosis and anabolic
eroids abuse may be explained by increase in lean body
ass and potential direct nephrotoxic effects of anabolic
eroids.1 Furthermore, this drug modulates steroid hydroxy-
se activity predisposing to hypercalcemia.4 The association
f vitamin A toxicity and hypercalcemia is rare but well rec-
gnized. It is attributed to a direct effect on bone (activation
f bone reabsorption with increased osteoclast activity),5 on
e parathyroid, or in both.6 According to Chertow et al.,
tamin A stimulate PTH secretion in bovine parathyroid
ssue and in men.6,7 The minimum dose of vitamin A
quired to produce hypercalcemia cannot be stated with cer-
inty; toxicity has been described from doses ranging from
,000 to 500,000 IU/day.5 Although we did not measure the
lue of vitamin A in blood, the patient injected more  than
100,000 IU/month (which correspond 70.000 IU of vitamin
/day) for more  than 4 years, which is compatible with toxicity.
ypercalcemia is a well-known but uncommon complication
f vitamin D intake.8 Usually results from doses that exceed
,000 IU/day, and is generally associated with serum lev-
s of 25-hydroxyvitamin D that are well above 150 ng/mL.8
 this case, 60,000 IU of ergocalciferol were inject monthly
d serum vitamin D was in the upper limit of normal.
he tolerable upper level of daily vitamin D intake recently
t by the Institute of Medicine is 4000 IU.8 Vitamin A and
 can act synergistically to cause hypercalcemia. Contrary
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Table 1 – Laboratory evaluation
Parameter Reference range On admission 48 h One week Two weeks At discharge
Hemoglobin 14.3–18.3 g/dL 14.8 g/dL 13.1 13.6 12.9
Creatinine 0.6–1.2 mg/dL 1.2 3.8 1.92 1.4 0.7
Urea 20–44 mg/dL 52.93 125 84.4 43 36
Lipase 0–75 IU/L 612 456 321 63
Amylase 50–160 IU/L 2500 1430 234 88
Corrected Calcium 8.5–10.5 mg/dL 12.5 12.3 11.1 9.0
Albumin 2.9–5.2 g/dL 3.0 2.5 3.0 2.4
PTH 15–68.3 pg/mL 73.2 70.2 38 35
25-OH-VIT D 30–100 ng/mL 65.1 56.2 69.7
Phosphorus 2.5–4.5 mg/dL 3.8 3.0 3.2 4.0
Triglyceride 50–200 mg/dL 61 185
Fig. 1 – Evolution of physical tone during hospitalization.
to what we  were expecting, the patient described here pre-
sented with hypercalcemia and moderated increased serum
PTH, instead of suppression of the activity of this hormone
by multidrug and vitamin abuse. Multifactorial mechanisms
may be involved and some possible explanations are: vitamin
A intoxication may have had a leading role in the develop-
ment of hypercalcemia and itself may increase PTH secretion6;
parathyroid overactivity has been described in critical ill-
ness associated with sepsis and renal failure (life-threatening
tertiary hyperparathyroidism).9 Primary hyperparathyroidism
from adenoma or hyperplasia was excluded by negative imag-
ing studies and the restoration of serum calcium and PTH to
normal levels after discontinuation of the drugs. Finally, in the
case reported here there was a peculiar involvement of the
neck and the arms due to self-injection of mineral oil, more
apparent after the signiﬁcant weight loss observed (more than
30 kg) by the patient (Fig. 1). Biopsy of the affected skin revealed
multinucleated giant cells and inﬂammatory inﬁltrates.
These lesions, called parafﬁnomas, may have contributed to
In conclusion, clinicians need to be aware that AAS and
multivitamin abuse can occur with relative frequency and
their use can be surreptitious. The simultaneous occurrence
of nephrocalcinosis, nephrolithiasis, acute kidney injury and
acute pancreatitis may be a clue to the diagnosis of associated
chronic hypercalcemia.
r  e  f  e  r  e  n  c  e  s
1. Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes
MB,  Kunis C, et al. Development of focal segmental
glomerulosclerosis after anabolic steroid abuse. J Am Soc
Nephrol. 2010;21(1):163–72 [Pubmed].
2. Caldeira C, Neves WS, Cury PM, Serrano P, Baptista MA,
Burdmann EA. Rhabdomyolysis, acute renal failure, and
death after monensin ingestion. Am J Kidney Dis.
2001;38(5):1108–12 [Pubmed].
3. Daher EF, Silva Junior GB, Queiroz AL, Ramos LM,  Santos SQ,
Barreto DM, et al. Acute kidney injury due to anabolic steroidhypercalcemia due to PTH-independent, extrarenal produc-
tion of 1,25-dihydroxy-vitamin D by activated mononuclear
cells.10and vitamin supplement abuse: report of two cases and a
literature review. Int Urol Nephrol. 2009;41(3):717–23
[Pubmed].
600  n e f r o l o g i a. 2 0 1 5;3 5(6):597–601
4. Samaha AA, Nasser-Eddine W,  Shatila E, Haddad JJ, Wazne J,
Eid  AH. Multi-organ damage induced by anabolic steroid
supplements: a case report and literature review. J Med Case
Rep. 2008;2:340 [Pubmed].
5. Penniston KL, Tanumihardjo SA. The acute and chronic toxic
effects of vitamin A. Am J Clin Nutr. 2006;83(2):191–201
[Pubmed].
6. Miller P, Sweny P, Persaud JW,  Varghese Z, Farrington K, Chan
MK,  et al. The effects of vitamin A toxicity on calcium and
lipid metabolism in chronic renal failure. Proc Eur Dial
Transplant Assoc. 1981;18:573–8 [Pubmed].
7. Chertow BS, Williams GA, Norris RM, Baker GR, Hargis GK.
Vitamin A stimulation of parathyroid hormone: interactions
with calcium, hydrocortisone, and vitamin E in bovine
parathyroid tissues and effects of vitamin A in man. Eur J Clin
Invest. 1977;7(4):307–14 [Pubmed].
8. Rosen CJ. Clinical practice. Vitamin D insufﬁciency. N Engl J
Med. 2011;364(3):248–54 [Pubmed].
9. Jeffries CC, Ledgerwood AM, Lucas CE. Life-threatening
tertiary hyperparathyroidism in the critically ill. Am J Surg.
2005;189(3):369–72 [Pubmed].
10. Gyldenlove M, Rorvig S, Skov L, Hansen D. Severe
hypercalcaemia, nephrocalcinosis, and multiple parafﬁnomas
caused by parafﬁn oil injections in a young bodybuilder.
Lancet. 2014;383(9934):2098 [Pubmed].
Claudia Bentoa,∗, Pedro Velhob, Maurício Carvalhob
a Servicio de Nefrología, CHTMAD - Vila Real, Vila Real, Portugal
b Servicio de Nefrología, Hospital de clinicas, Curitiba, Brazil
∗ Corresponding author at: Servicio de Nefrología, CHTMAD - Vila
Real, Avenida da Noruega, Lordelo, Vila Real 5000-508, Portu-
gal.
E-mail address: claudiaqbento@gmail.com (C. Bento).
2013-2514/© 2015 Sociedad Espan˜ola de Nefrol-
ogía. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.nefroe.2015.10.008
Valvular  calciﬁcations  in  chronic  kidney  disease:  Mineral
and bone  disease  or  previous  cardiovascular  risk?
Response
Calciﬁcaciones  valvulares  en  enfermedad  renal  crónica:¿enfermedad
mineral  ósea  o  riesgo  cardiovascular  previo?  Respuesta
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e  thank Dr. Bocanegra et al. for their interest in our study.1
In their comments, they pointed out that the methods sec-
on did not provide the values of phosphorus, calcium, and
H of the patients with and without valvular calciﬁcation
C). Values of these parameters were not shown because we
ecided to include in the table only those values with differ-
ces that were statistically signiﬁcant. Therefore, the values
f phosphorus, being signiﬁcantly different, were shown in
ble 1 of the original article. In our study, the values of cal-
um and PTH were similar in both patient groups, with and
ithout VC, and were within the range recommended by the
DOQI, as shown in Table 1 of this letter.
Regarding the comment on the multivariate analysis of fac-
rs associated with VC, we  would like to offer the following
ariﬁcation: the analysis performed included those variables
at showed a statistically signiﬁcant difference between
oups, including phosphorus. The analysis also included
ther variables that could have been associated with the calci-
cation process: lipids, C-reactive protein, PTH, and calcium,Please cite this article as: Perales CS, de Castroviejo EVR. Calciﬁcacion
ineral ósea o riesgo cardiovascular previo? Respuesta. Nefrología. 2015ough these variables were inadvertently omitted from text.
e  therefore thank Bocanegra et al. for the opportunity to pro-
de this information. The results of the multivariate analysis
owed that older age and lower albumin level were indepen-
ently associated with VC, as shown in Table 3 of the article.
As Bocanegra et al. pointed out, our study demonstrates
at the presence of VC is an independent risk factor for car-
iovascular events and cardiovascular death, although it does
ot establish the factors involved in the development of VC,
ther than older age and lower albumin level. Similarly to
ther studies,2 our study found no association between VC and
e biochemical abnormalities of bone mineral metabolism
at are measured in routine clinical practice. Likewise, there
as no association with atherogenic comorbidities nor with
tablished atherosclerosis. This association has not been
aluated in most of the studies on VC in incident dialysis
atients. In prevalent dialysis patients, VC has been associated
ith a history of cardiovascular events and left ventricular
ypertrophy.3
The precise cellular and molecular mechanisms that
rive cardiac and vascular ectopic calciﬁcation are not fullyes valvulares en enfermedad renal crónica:¿enfermedad
;35:600–601.
